CClinicalTrials.gg
CompletedNCT04620629Updated Mar 6, 2023

The Effect of Probiotic Supplement on Urinary D-lactic Acid Level in Newborns

An observational study in Antibiotic Side Effect, sponsored by H. Tolga Çelik. Completed at 1 site in Turkey. Open to participants aged 1 Day to 28 Days. Per ClinicalTrials.gov, last updated 2023-03-06.

Sponsored by H. Tolga Çelik · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
71
Ages
1 Day to 28 Days
Sex
All
01

Study summary

It is thought that prophylactic enteral probiotics in newborns may play a role in the prevention of infection and NEC-related morbidity by preventing bacterial migration in the mucosa, reducing their number by competing with pathogenic bacteria, providing microbial balance, and increasing intestinal immunity.

In our study, it was determined to detect normal D-lactic acid levels in urine in late premature (babies born after 34 weeks of gestation) and term babies, to show the negative effect of antibiotic treatment on the intestinal flora indirectly by measuring urinary D-lactic acid, and the probiotic support in babies using antibiotics was disrupted. The investigators aim to investigate hypothesis that it will have a corrective effect on the intestinal flora by comparing urinary D-lactic acid levels.

Read the detailed description

Lactic acid exists as two optical isomers, L-lactic acid and D-lactic acid. These isomers are metabolized to or synthesized from pyruvate by the action of isomer-specific enzymes (L-lactate dehydrogenase and D-lactate dehydrogenase). Mammals, including humans, do not possess D-lactate dehydrogenase, and therefore D-lactate production in human tissue is very limited. The endogenous single D-lactate synthesis known in man is carried out by glyoxalase. In this pathway, methylglyoxal is converted into D-lactate by the enzymes glyoxalase-1 and glyoxalase-2. Due to this restricted production, the blood D-lactate level in healthy people is so low that L-lactate is the major physiological enantiomer of lactate in the human body.

The bacterial flora in the human gastrointestinal tract has the ability to produce L and / or D-lactate depending on the amount of L-LDH and D-LDH present. Some strains of bacteria have the enzyme DL-lactate racemase to convert one isomer to another. Therefore, racemization reactions can further increase the amount of D-lactate isomers present in the column. Although there is no D-lactate dehydrogenase enzyme in humans, D-Lactate is metabolized into pyruvate by the enzyme D-2-hydroxy acid dehydrogenase (D-2-HDH), an intramitochondrial flavoprotein with high activity in the liver and renal cortex. The kidney's threshold for D-lactate is much lower than L-lactate and is efficiently excreted in urine as well as metabolic clearance. Thus, under normal conditions, D-lactate produced by tissue metabolism or bacterial fermentation in the gut; It does not cause a clinically significant increase in lactate in blood, urine or feces.

D-lactic acidosis is a well-defined complication of short bowel syndrome due to the combination of altered gastrointestinal tract anatomy and abnormal bacterial flora. Many case reports reported in the literature are associated with short bowel syndrome secondary to various causes. There are studies investigating the effects of fermented formulas and probiotics on D-lactic acid in healthy babies. In these studies, no increased risk for D-lactic acidosis was found in healthy infants fed with probiotic supplemented formulas.

Considering the studies on newborns; In babies with necrotizing enterocolit, it has been shown that urinary D-lactate excretion increased as a result of increased enteric bacterial activity. In another study, plasma D-lactic acid level was found to be high in premature babies with necrotizing enterocolitis. However, more detailed studies on newborns are needed.

02

Conditions studied

  • Antibiotic Side Effect
03

In context

Lead sponsor

This is the only study on the registry with H. Tolga Çelik as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Healthy newborns who born after 34 weeks of gestation, late preterm and term infants receiving antibiotic treatment,

Inclusion criteria

  • Late preterm and term babies
  • Babies who are fed only breast milk and / or formula with breast milk
  • Babies who have to be given formula support in the early period because they cannot receive breast milk or are not sufficient in the neonatal period, therefore probiotic support is started and continues
  • Babies whose antibiotic treatment is started in the neonatal period
  • Babies whose parents consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Hypoxic ischemic encephalopathy
  • Babies with urinary tract infections
  • Babies with a history of premature rupture of membranes
  • Chromosomal abnormality
  • Those with major congenital anomaly, gastrointestinal system anomaly
  • Presence of any known immunodeficiency,
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
71 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • control group

    Late premature and term babies without any disease

  • probiotic group

    Babies whose probiotic support is started and continues because they cannot receive breast milk, and whose antibiotic treatment is started in the neonatal period.

  • antibiotic group

    Babies who receives antibiotic treatment in the neonatal period and does not receive probiotic support before.

06

What researchers measure

Primary outcomes

  1. urinary D-lactate levels

    Urinary D-lactic acid levels of infants in the subgroup taking probiotics and not taking probiotics will be compared at the end of the 4th week.

    Time frame: 4 weeks

07

Study locations

1 site
  • Hacettepe University
    Ankara, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04620629
Lead sponsor
H. Tolga Çelik
Responsible party
H. Tolga Çelik (Principal Investigator, Hacettepe University) — Sponsor-investigator
First posted
Nov 9, 2020
Start date
Feb 1, 2020
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020
Last update
Mar 6, 2023

Study contacts

Tolga Celik
principal investigator · Hacettepe University

Oversight

FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion